Tonix Pharmaceuticals Holding (TNXP) Key Ratios
$13.09
As on 04-Sep-2026 13:36EDT
Market cap
$233 Mln
Revenue (TTM)
$29 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 96.92 | 577.88 | 196.02 | -12.63 | 58.45 |
| EBIT | -0.89 | -43.44 | -96.10 | -11.57 | -170.80 |
| Net Profit | -0.89 | -43.44 | -96.10 | -11.57 | -171.02 |
| EPS | 16.87 | 36.82 | 99.43 | 25.99 | 14.87 |
| Book Value | -- | -- | -53.28 | -97.60 | -87.31 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -1,072.51 | -1,114.81 | -548.64 | -945.54 | -770.20 |
| Net Margin
| -- | -368,848.00 | -548.64 | -- | -- |
| Return on equity
| -81.73 | -71.88 | -68.32 | -64.48 | -106.12 |
| Return on Capital
| -78.50 | -69.81 | -- | -63.39 | -99.95 |
| Return on Assets
| -66.56 | -60.68 | -48.10 | -56.37 | -81.95 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.01 | 0.04 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
-63.39
|
-99.95
|
-72.17
|
-53.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-68.32
Lower than Peers by 27.92
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-68.32
|
-64.48
|
-106.12
|
-74.61
|
-54.01
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-48.10
Lower than Peers by 17.12
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-48.10
|
-56.37
|
-81.95
|
-61.38
|
-49.30
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-548.64
Lower than Peers by 465.02
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-548.64
|
-945.54
|
-770.20
|
-1,501.78
|
-1,241.73
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-548.64
Lower than Peers by 455.97
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-548.64
|
-946.22
|
-1,288.25
|
-1,501.78
|
-1,274.00
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
196.02
Higher than Peers by 142.07
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
196.02
|
0.30
|
0.30
|
-0.14
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-96.10
Lower than Peers by 95.30
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-96.10
|
-59.41
|
33.36
|
-4.07
|
-21.43
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-96.10
Lower than Peers by 88.80
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-96.10
|
4.63
|
-11.47
|
-1.44
|
-24.72
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
99.43
Higher than Peers by 84.78
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
99.43
|
0.75
|
1.00
|
-0.01
|
-1.49
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-41.72
Lower than Peers by 31.55
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-41.72
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
0.01
|
0.04
|
0.09
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
0.00
|
0.00
|
0.00
|
0.02
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.61
Higher than Peers by 0.80
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
6.61
|
7.42
|
6.50
|
2.53
|
7.19
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
6.61
Higher than Peers by 0.91
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
6.61
|
7.23
|
6.04
|
1.78
|
7.64
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-1,793.00
Lower than Peers by 1,790.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
-1,793.00
|
-1,392.49
|
-63.00
|
--
|
-14.17
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
40.56
Higher than Peers by 21.42
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
40.56
|
74.43
|
78.30
|
59.09
|
89.10
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.09
Higher than Peers by 0.02
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
0.09
|
0.06
|
0.06
|
0.04
|
0.04
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
246.06
|
226.05
|
297.00
|
319.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
307.49
|
530.47
|
235.13
|
-26.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
269.94
|
195.87
|
456.47
|
34.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
283.61
|
560.65
|
75.66
|
258.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
-1.07
|
-0.01
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.05
Lower than Peers by 4.14
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
1.05
|
0.54
|
0.01
|
--
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.94
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
0.94
|
0.60
|
1.25
|
0.13
|
1.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
233
Higher than Peers by 87
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tonix Pharmaceuticals Holding (TNXP)
|
233
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|